Herein, a series of heterocyclic Bcr-Abl kinase inhibitors with different structural scaffolds were designed and synthesized. HTScan Abll kinase assay kit was used for the inhibitory test. Some modest inhibitors were obtained.
INTRODUCTION
The Bcr-Abl gene is the results of Philadelphia translocation (reciprocal translocation between chromosome 9 and 22), which is associated with chronic myelogeneous leukemia (CML). The end product is a tyrosine kinase.
1 ' 2 Inhibitors of this kinase are potential drugs against CML. The success of using STI-571 (imatinib, Gleevec) to bring complete remission in CML patients has spurred a great deal of interest in developing new inhibitors of this tyrosine kinase as potential drugs. 3 ' 5 In addition, drug resistance development is a major issue associated with Gleevec. 6 Therefore, there is truly a need for new inhibitors in order to overcome drug resistant problems. Several new Bcr-abl kinase inhibitors have been evaluated in clinical trials. 7 ' 8 However, the need for new inhibitors has not diminished because drug resistance is a continuous issue. Herein, we are interested in the development of Bcr-abl kinase inhibitors using structural scaffolds that are completely different from existing inhibitors. The hope was that such compounds might offer advantage in overcoming drug resistant problems.
In carrying out the work, we first were interested in building a pharmacophore model using existing inhibitors and PD-173955 (8) (Figure I ). In this study, the closed conformation (PDB entry: 1IEP) of the enzyme was selected as the docking model. The 3D structure of STI-571 was derived from X-ray structure (PDB entry: 1IEP). Other 3D structures were generated by AMI semi-empirical quantum mechanics calculation. All ligands were then assigned with * e-mail: wang@gsu.edu
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Fig. 1: Known inhibitors for Bcr-Abl kinase used in this study
Gastiger-Hückel partial charges using SYBYL. DOCK 5.2 was used to dock these ligands into active site against Bcr-Abl kinase. Figure 2 shows the docking conformations of these ligands against Bcr-Abl kinase. Chen et al.
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From Figure 3 4 ). Based on all these features, we have designed the compounds in Figure 5 as potential inhibitors. 
RESULTS AND DISCUSSION
Scheme 1 describes the synthesis of analogs of benzo [5] imidazoles (9a-9j). Specifically, starting from 12 the bromo-substituted compounds (14a, 14b) were generated in two steps through ieri-butyl carbamate protection (13a. 13b) and bromination (14a, 14b) according to general literature procedures. 9 '" The final compounds (9a-9j) were obtained 
Benzo[ß]thiophene-2-carbothioates 10a-s were synthesized starting with the amidation of aniline 16 (Scheme 2).
Acyl chlorides 20 were synthesized from the α, ß-unsaturated carboxylic by reacting with thionyl chloride (17) under reflux conditons. 12 " 13 Reaction of acylchloride 20 and phenylacetamides 18 in presence of Et 3 N in benzene gave the final products (10a-10s) 81-95% yields.
Thiadiazole benzamides (lla-llt) were prepared starting with the substitution of the chloride in 21 with thiadiazole thiol (22). This was followed by amidation to give the final products lla-t in 50-73% yields.
For the inhibitor assay, an HTScan Abll kinase assay kit (#7905 from cell signaling technology) was used. Among all the compounds tested, 9 were observed to have inhibition activities against Abl kinase with IC 50 below 1 mM (9b, 9g, lOd, 10c, 10k, 10p, lOq, llj, and lln), and compound lOq showed 1C 50 below 100 μΜ (Table 1) . In analyzing the inhibition results, we were interested in achieving some basic understanding of the structural features, which are important for future optimization work. From the compounds listed above, one can see that the benzo[ß]thiophene-2-carbothioate core structure seem to confer better inhibition effect than the thiadiazol-benzamides and benzo [5] imidazoles. For example, compounds 10p and lOq have the best inhibitory effects. There are five benzo[ß]thiophene-2-carbothioate compounds (lOd, lOe, 10k, 10p, and lOq) with IC 50 values below 1 mM, while the thiadiazol-benzamide and the benzo [6] imidazole scaffolds combined only have four compounds (9b, 9g, llj, and lln)
with IC 50 in the range of 500-1000 μΜ.
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Scheme 2. The synthesis of compounds lOa-s
As for the core thiadiazol-benzamide structure, para substitution on the phenyl group seems to favor activities. For example, adding a bromo group at the para-position of the phenyl ring resulted in significantly improved activities from an IC 50 of 1 mM (101) to 175 μΜ (10p). However, no improvement was observed if the substituent was at the meta-or ort ho-position. This seems to be true for all the compounds tested. All the active compounds have para-
US
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substituent on the phenyl ring. Meanwhile, bulky groups also do not seem to favor the inhibitory effects. Such are the cases with compounds lOr and 10s.
In comparing between the phenoxy and phenylthiol groups in the benzo [5] imidazole compounds, higher inhibition activities of the phenylthiol compound were observed. For example, both compounds 9b and 9g have lower IC 50 (<1 mM) compared to compounds 9d and 9i, though para-C 1 probably also played some important roles as discussed above.
OoN N-N 22 Though only modest inhibitors were obtained, considering that these compounds were based on de novo design the results are very significant and lay a foundation for future optimization in search of new Bcr-abl kinase inhibitors with a structural scaffold that is completely different from other known inhibitors.
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EXPERIMENTAL SECTION Enzyme assay
All the test compounds were dissolved in DMSO to the concentration 20 mM as stock solution. The compounds were tested by using the HTScan Abll kinase assay kit (cell signaling technology #7905). The experiment was performed according to the standard protocol described in the brochure for the kit. Briefly, the tested compounds were diluted to the test concentration and added to 96-well plates. This was followed by the addition of ATP, substrate, and the enzyme. After incubation and washing, primary and secondary antibodies were added. Fluorescence intensity was detected by using a Perkin-Elmer microplate reader (λ^χ 340 nm, ^"615 nm). IC 50 values were estimated based on the concentration that caused 50% reduction of in fluorescence.
Chemistry
Triethylamine and pyridine were distilled over KOH pellets and stored in a septum-sealed flask. Solvents were dried by heating under refluxing for at least 12 h over P 2 0 5 (dichloromethane) or sodium/benzophenone (benzene, THF), and
were freshly distilled prior to use. All new compounds gave satisfactory 1H NMR (400 or 300 MHz) 13C NMR (100 or 75 MHz) and high resolution mass spectra (ESI). Melting points were determined on an XT-4 melting point apparatus and were uncorrected.
General procedure for synthesis of tert-butyl 2-aryl -lH-benzo[d]imidazole-l-carboxylate
To a solution of 2-arylbenzimidazole (10 mmol) in DMF (30 mL) was added K 2 C0 3 (12 mmol). Then the mixture was stirred for 40 min. A solution of di-/er/-butyl dicarbonate (11 mmol) in DMF (10 mL) was added to the reaction mixture, and the reaction was allowed to continue for 5 h until no starting material remained. The solvent was removed, and the residue was dissolved in EtOAc, washed with 5% HCl, saturated NaHC0 3 and brine, dried with anhydrous Na 2 S0 4 . It was purified by column chromatography (petroleum ether/ethyl acetate = 1/6) to afford the desired products. 
fcr/-Butyl 2-/n-tolyl-lJ/-benzo|rf]imidazole-l-carboxylate
Bromination of terf-butyl 2-aryl -l//-benzo[rf]imidazole-I-carboxylate
A stirred solution of tert-butyl 2-aryl-1 H-benzo[d\imidazole-1 -carboxylate (5 mmol) and benzoyl peroxide (lmmol) in CC1 4 (50 mL) was refluxed for 2 h. The solution was cooled, filtered, and concentrated under reduced pressure. The Chen et al.
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crude product was purified by column chromatography (petroleum ether/ethyl acetate = 1/6) to afford the desired products. 
tert-Butyl 2-(3-(bromomethyl)phenyl)-l//-benzo|</]imidazole-l-carboxylate
General procedure for the synthesis of compounds 9a-j
To the solution of phenol or benzenethiol (5 mmol) in DMF (5 mL) was added K 2 C0 3 (6 mmol). The mixture was extracted with EtOAc, and the extract was dried with anhydrous Na 2 S0 4 , filtered, and purified by column chromatography (petroleum ether/ethyl acetate = 2/1) to give the desired products. 
2-(3-(PhenyIthiomethyl)phenyl)-l//-benzo|</]imidazole (9a)
2-(3-((4-Chlorophenylthio)methyI)phenyl)-l//-benzo|</| imidazole (9b):
White solid (70% yield); mp 159-160 °C.
2-(3-((4-Nitrophenoxy)methyl)phenyl)-l//-benzo[</]imidazole (9c):
Yellowish solid (60% yield); mp 213-214 °C.
2-(3-(Phenoxymethyl)phenyl)-l//-benzo|</|imidazole (9d):
White solid (65% yield); mp 164-165 °C.
2-(3-((2-Nitrophenoxy)methyl)phenyI)-lfi-benzo|</|imidazole (9e):
Yellowish solid (50% yield); mp 229-231 °C.
2-(4-(Phenylthiomethyl)phenyl)-l//-benzo|</)imidazole (9f):
White solid (73% yield); mp 211-212 °C.
2-(4-((4-Chlorophenylthio)methyl)phenyl)-l//-benzo[</]imidazole (9g):
White solid (70% yield); mp 210-211 °C.
2-(4-((4-Nitrophenoxy)methyl)phenyl)-l//-benzo[rf]imidazole (9h):
Yellowish solid (53% yield); mp 220-221 °C.
2-(4-(PhenoxymethyI)phenyl)-l//-benzo|</|imidazole (9i):
White solid (60% yield); mp 202-203 °C .
2-(4-((2-Nitrophenoxy)methyl)phenyl)-l//-benzo|</]imidazole (9j):
Yellowish solid (59% yield); mp 217-218 °C.
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General procedure for the synthesis of compounds 10a
s. α-Mercaptoacetanilide (1 mmol) was dissolved in benzene (5 mL), then triethylamine (1.5 mmol) and benzo[£]thiophene-2-carboxyl chloride (1 mmol) were added to the solution. The reaction mixture was stirred for 5 h at room temperature, filtered, and the solid was dissolved in chloroform, washed with water, dried and concentrated to
give the desired products.
2-Oxo-2-(phenylamino)ethyl 3-chlorobenzo[A]thiophene-2-carbothioate (10a)
White 
2-(2-Chlorophenylamino)-2-oxoethyl 3,6-dichlorobenzo[6]thiophene-2-carbothioate (10m):
White solid (93% yield); mp 173-174 °C.
2-(3-Chlorophenylamino)-2-oxoethyl 3,6-dichlorobenzo[ft|thiophene-2-carbothioate (1 On):
White solid (89% yield); mp 184-185 °C. 
2-(4-
2-(4-Bromophenylamino)-2-oxoethyl 3,6-dichlorobenzo[Ä]thiophene-2-carbothioate (10p):
White solid (90% yield); mp 208-209 °C. General procedure for the synthesis of compounds lla-t.
2-(p-
The solution of 5-(2,4-dinitrophenythio)-l,3,4-thiadiazol-2-ylamine or 2-(5-amino-I,3,4-thiadiazol-2-ylthio)-5-nitrobenzonitrile (0.5 mmol) in pyridine (5 mL) was treated with substituted benzoyl chloride (0.6 mmol), heated at 100 °C for 3 h, and the reaction mixture was poured into ice water containing concentrated hydrochloride acid (5 mL).
The precipitate was filtered. The solid was purified by column chromatography (petroleum ether/ethyl acetate = 2/1) to afford the desired products.
A'-|5-(2,4-Dinitrophenylthio)-l,3,4-thiadiazol-2-yl|-benzamide (11a) Chen et al.
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CONCLUSIONS
Based on pharmacophore modeling, a series of heterocylic inhibitors of Bcr-Abl kinase was designed and synthesized. Although only modest inhibition activities were obtained, future optimization of the new structural scaffold identified could lead potent inhibitors effect against Bcr-Abl kinase.
